Shanghai Fosun Pharmaceutical (Group) Past Earnings Performance
Past criteria checks 0/6
Shanghai Fosun Pharmaceutical (Group)'s earnings have been declining at an average annual rate of -5.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 9.6% per year. Shanghai Fosun Pharmaceutical (Group)'s return on equity is 4.7%, and it has net margins of 5.1%.
Key information
-5.9%
Earnings growth rate
-6.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 9.6% |
| Return on equity | 4.7% |
| Net Margin | 5.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Fosun Pharmaceutical (Group) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 41,611 | 2,114 | 13,512 | 3,839 |
| 30 Jun 24 | 40,467 | 1,835 | 13,393 | 4,074 |
| 31 Mar 24 | 40,686 | 2,009 | 13,938 | 4,207 |
| 31 Dec 23 | 41,400 | 2,386 | 14,198 | 4,346 |
| 30 Sep 23 | 43,029 | 3,578 | 14,379 | 4,595 |
| 30 Jun 23 | 43,999 | 3,972 | 14,358 | 4,609 |
| 31 Mar 23 | 44,437 | 4,261 | 13,714 | 4,461 |
| 31 Dec 22 | 43,952 | 3,731 | 13,061 | 4,302 |
| 30 Sep 22 | 43,586 | 3,600 | 12,730 | 4,286 |
| 30 Jun 22 | 43,406 | 3,782 | 12,585 | 4,103 |
| 31 Mar 22 | 41,340 | 4,338 | 12,514 | 4,006 |
| 31 Dec 21 | 39,011 | 4,729 | 12,401 | 3,837 |
| 30 Sep 21 | 35,253 | 4,749 | 11,695 | 3,332 |
| 30 Jun 21 | 33,231 | 4,430 | 11,636 | 3,153 |
| 31 Mar 21 | 32,483 | 3,933 | 11,682 | 2,944 |
| 31 Dec 20 | 30,307 | 3,663 | 11,204 | 2,795 |
| 30 Sep 20 | 29,460 | 3,737 | 11,628 | 2,629 |
| 30 Jun 20 | 28,441 | 3,520 | 11,647 | 2,396 |
| 31 Mar 20 | 27,736 | 3,187 | 11,989 | 2,140 |
| 31 Dec 19 | 28,585 | 3,322 | 12,524 | 2,041 |
| 30 Sep 19 | 28,004 | 2,677 | 12,376 | 1,655 |
| 30 Jun 19 | 27,232 | 2,664 | 12,048 | 1,620 |
| 31 Mar 19 | 25,929 | 2,714 | 11,310 | 1,596 |
| 31 Dec 18 | 24,918 | 2,708 | 10,734 | 1,480 |
| 30 Sep 18 | 23,716 | 2,799 | 10,136 | 1,441 |
| 30 Jun 18 | 22,040 | 2,996 | 9,315 | 1,274 |
| 31 Mar 18 | 20,372 | 3,092 | 8,195 | 1,304 |
| 31 Dec 17 | 18,534 | 3,124 | 7,537 | 1,027 |
| 30 Sep 17 | 16,951 | 3,047 | 6,856 | 700 |
| 30 Jun 17 | 16,045 | 2,993 | 6,421 | 461 |
| 31 Mar 17 | 15,283 | 2,908 | 6,404 | 0 |
| 31 Dec 16 | 14,629 | 2,805 | 6,028 | 0 |
| 30 Sep 16 | 14,173 | 2,745 | 5,516 | 0 |
| 30 Jun 16 | 13,624 | 2,657 | 5,213 | 0 |
| 31 Mar 16 | 13,034 | 2,557 | 4,898 | 0 |
| 31 Dec 15 | 12,609 | 2,459 | 4,724 | 0 |
| 30 Sep 15 | 12,438 | 2,429 | 4,575 | 0 |
| 30 Jun 15 | 12,408 | 2,398 | 4,381 | 0 |
| 31 Mar 15 | 12,168 | 2,234 | 4,159 | 0 |
| 31 Dec 14 | 12,026 | 2,113 | 4,007 | 0 |
| 30 Sep 14 | 11,587 | 2,207 | 3,760 | 0 |
| 30 Jun 14 | 11,026 | 1,987 | 3,570 | 0 |
| 31 Mar 14 | 10,598 | 1,646 | 3,465 | 0 |
| 31 Dec 13 | 9,996 | 1,583 | 3,273 | 0 |
Quality Earnings: 08HH has a large one-off loss of CN¥1.1B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 08HH's current net profit margins (5.1%) are lower than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 08HH's earnings have declined by 5.9% per year over the past 5 years.
Accelerating Growth: 08HH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 08HH had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: 08HH's Return on Equity (4.7%) is considered low.